Widen RH - Search Results

1

Lymphocyte recovery after breast cancer treatment and mindfulness-based stress reduction (MBSR) therapy.

Lengacher CA, Kip KE, Post-White J, Fitzgerald S, Newton C, Barta M, Jacobsen PB, Shelton MM, Moscoso M, Johnson-Mallard V, Harris E, Loftus L, Cox C, Le N, Goodman M, Djeu J, Widen RH, Bercu BB, Klein TW. Lengacher CA, et al. Among authors: widen rh. Biol Res Nurs. 2013 Jan;15(1):37-47. doi: 10.1177/1099800411419245. Epub 2011 Nov 14. Biol Res Nurs. 2013. PMID: 22084404 Clinical Trial.

2

Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer.

Lengacher CA, Johnson-Mallard V, Post-White J, Moscoso MS, Jacobsen PB, Klein TW, Widen RH, Fitzgerald SG, Shelton MM, Barta M, Goodman M, Cox CE, Kip KE. Lengacher CA, et al. Among authors: widen rh. Psychooncology. 2009 Dec;18(12):1261-72. doi: 10.1002/pon.1529. Psychooncology. 2009. PMID: 19235193 Clinical Trial.

3

Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients.

Reich RR, Lengacher CA, Kip KE, Shivers SC, Schell MJ, Shelton MM, Widen RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW. Reich RR, et al. Among authors: widen rh. Biol Res Nurs. 2014 Oct;16(4):429-37. doi: 10.1177/1099800413519494. Epub 2014 Jan 28. Biol Res Nurs. 2014. PMID: 24477514 Free PMC article. Clinical Trial.

4

Differential suppression of T-cell subpopulations by thc (delta-9-tetrahydrocannabinol).

Pross SH, Klein TW, Newton CA, Smith J, Widen R, Friedman H. Pross SH, et al. Int J Immunopharmacol. 1990;12(5):539-44. doi: 10.1016/0192-0561(90)90118-7. Int J Immunopharmacol. 1990. PMID: 2170281

5

Role of Toll-like receptor 9 in Legionella pneumophila-induced interleukin-12 p40 production in bone marrow-derived dendritic cells and macrophages from permissive and nonpermissive mice.

Newton CA, Perkins I, Widen RH, Friedman H, Klein TW. Newton CA, et al. Among authors: widen rh. Infect Immun. 2007 Jan;75(1):146-51. doi: 10.1128/IAI.01011-06. Epub 2006 Oct 23. Infect Immun. 2007. PMID: 17060467 Free PMC article.

6

Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes.

Agudelo M, Newton C, Widen R, Sherwood T, Nong L, Friedman H, Klein TW. Agudelo M, et al. J Neuroimmune Pharmacol. 2008 Mar;3(1):35-42. doi: 10.1007/s11481-007-9088-9. Epub 2007 Sep 27. J Neuroimmune Pharmacol. 2008. PMID: 18247126 Free PMC article.

7

Identification of transcription start sites and preferential expression of select CB2 transcripts in mouse and human B lymphocytes.

Sherwood TA, Nong L, Agudelo M, Newton C, Widen R, Klein TW. Sherwood TA, et al. J Neuroimmune Pharmacol. 2009 Dec;4(4):476-88. doi: 10.1007/s11481-009-9169-z. Epub 2009 Sep 16. J Neuroimmune Pharmacol. 2009. PMID: 19757078 Free PMC article.

8

Suppression of T lymphocyte subpopulations by THC.

Pross S, Newton C, Klein T, Widen R, Smith J, Friedman H. Pross S, et al. Adv Exp Med Biol. 1991;288:113-7. doi: 10.1007/978-1-4684-5925-8_12. Adv Exp Med Biol. 1991. PMID: 1659126 No abstract available.

9

Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes.

Noe SN, Newton C, Widen R, Friedman H, Klein TW. Noe SN, et al. J Neuroimmunol. 2000 Oct 2;110(1-2):161-7. doi: 10.1016/s0165-5728(00)00349-0. J Neuroimmunol. 2000. PMID: 11024546

10

Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation.

Lee SF, Newton C, Widen R, Friedman H, Klein TW. Lee SF, et al. Eur J Pharmacol. 2001 Jul 6;423(2-3):235-41. doi: 10.1016/s0014-2999(01)01122-0. Eur J Pharmacol. 2001. PMID: 11448490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page